Cyber security company Appthority raises $10 mln

By Alastair Goldfisher — 4 weeks ago

San Francisco-based Appthority, a provider of mobile enterprise security services, announced it has raised $10 million in Series B funding from existing investors U.S. Venture Partners and Venrock, as well as new investors Blue Coat Systems and Knollwood Investment Advisory. The company previously raised $6.25 million in a Series A round in 2012.

Continue

VeloCloud fetches $27 mln Series C

By Iris Dorbian — 4 weeks ago

Mountain View, California-based VeloCloud Networks Inc, a cloud-delivered SD-WAN company, has raised $27 million in Series C funding. March Capital Partners led the round with participation from other investors that included Cisco Investments, New Enterprise Associates and Venrock.

Continue

Shape Security nabs $25 mln Series D

By Iris Dorbian — 4 weeks ago

Silicon Valley-based cyber security company Shape Security has secured $25 million in Series D funding. The investors included Baseline Ventures, Northern Light, Epic Ventures, Kleiner Perkins Caufield & Byers, Venrock, Norwest Venture Partners, Google Ventures and Tomorrow Ventures.

Continue

VC-backed Edge Therapeutics goes public

By Iris Dorbian — 4 months ago

Berkeley Heights, New Jersey-based Edge Therapeutics, a biotech company focused on developing therapies for neurological conditions, has debuted its IPO after pricing its over 7.3 million shares at $11 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “EDGE.” Leerink Partners and Credit Suisse are serving as the lead underwriters. Edge Therapeutics’ backers included Venrock, Sofinnova Ventures, Janus Capital Management LLC, New Leaf Venture Partners and BioMed Ventures.

Continue

VC-backed Aeglea BioTherapeutics promotes York to CFO

By Iris Dorbian — 4 months ago

Aeglea BioTherapeutics Inc, a biopharmaceutical company focused on treating tumor metabolism, has promoted Charles N. York to chief financial officer. Previously, York was the company’s vice president of finance and accounting. He first joined Aeglea in 2013, acting intially as a consultant before becoming a full-time employee during the summer of 2014. Aeglea’s backers include Lilly Ventures, Novartis Venture Fund, UT Horizon Fund, OrbiMed, Jennison Associates (on behalf of clients), Venrock, RA Capital Management, Rock Springs Capital, Ally Bridge Group and Cowen Investments.

Continue

New Leaf Venture leads $25 mln funding in Kyruus

By Chris Witkowsky — 5 months ago

New Leaf Venture Partners led a $25 million funding round in Kyruus, an enterprise software company for hospitals. Other investors in the funding included Providence Health & Services, Leerink Capital Partners and McKesson Ventures. Existing investors Venrock, Highland Capital Partners, Lux Capital and Fidelity Biosciences also participated in the funding. Sam Brasch, venture partner at New Leaf, has joined Kyruus’ board.

Continue

Kyruus nabs $25 mln

By Iris Dorbian — 5 months ago

Boston-based Kyruus, an enterprise software solutions provider that helps hospitals optimize patient access and referral management, has secured $25 million in funding. New Leaf Venture Partners led the round with participation from Providence Health & Services, Leerink Capital Partners, McKesson Ventures, Venrock, Highland Capital Partners, Lux Capital and Fidelity Biosciences.

Continue

Mevion Medical Systems racks up to $200 mln

By Iris Dorbian — 6 months ago

Littleton, Massachusetts-based Mevion Medical Systems, an advanced proton therapy systems provider, has secured up to $200 million in funding. The investors included HOPU Investments, YuanMing Capital, Caxton Alternative Management LP, ProQuest Investments, Venrock and CHL Medical Partners. In addition to the funding, Mevion and its lead backers will launch a joint venture in China focused on making and selling service proton therapy systems.

Continue

Venrock leads Series B round for Salsify

By Iris Dorbian — 7 months ago

Boston-based Salsify, a provider of product content management solutions, has raised $16.6 million in Series B funding. Venrock led the round with participation from other investors that included Matrix Partners and North Bridge.

Continue

Regenxbio racks up $70.5 mln Series D

By Iris Dorbian — 9 months ago

Rockville, Maryland-based Regenxbio, a gene therapy-focused biotech company, has closed $70.5 million in Series D funding. Vivo Capital, Venrock and Brookside Capital led the round with participation from other investors that included Janus Capital Management LLC, Perceptive Advisors LLC, Tourbillon Global Ventures, Sectoral Asset Management, Cormorant Asset Management LLC, Foresite Capital Management, Deerfield Management and Fidelity Biosciences. Chardan Capital Markets LLC was the placement agent.

Continue

Venrock, Aisling Capital lead $18.5 mln round for Spirox

By Luisa Beltran — 10 months ago

Spirox Inc. said Monday it closed an $18.5 million Series B round of financing led by Venrock and Aisling Capital. Existing investors Aperture Venture Partners, Correlation Ventures and Western Technology Investment also participated in the round. Menlo Park, California-based Spirox is a medical device company focused on developing minimally invasive technologies to treat nasal obstruction.

Continue

Edge Therapeutics racks up about $72.5 mln

By Iris Dorbian — 10 months ago

Berkeley Heights, New Jersey-based Edge Therapeutics, a biotech company focused on developing therapies for neurological conditions, has secured about $72.5 million in funding from two recent rounds. The company just closed $56 million in a Series C-2 funding round led by Venrock with participation from other investors that included Sofinnova Ventures, Janus Capital Management LLC, New Leaf Venture Partners and BioMed Ventures. The earlier round, which closed in December 2014, raised $16.5 million in Series C-1 funding. The investors for that round were not named. In connection to the Series C-2 round, Dr. Anders Hove of Venrock and Dr. James Healy, a managing partner at Sofinnova Ventures, have been added to Edge Therapeutics’ board of directors.

Continue

Niara grabs $20 million in Venrock-led round

By Iris Dorbian — 10 months ago

Sunnyvale, California-based Niara, a stealth security startup, has raised $20 million in Series B funding. Venrock led the round with participation from other investors that included New Enterprise Associates and Index Ventures. In conjunction with the funding, Doug Dooley of Venrock has been appointed to Niara’s board of directors.

Continue

RedSeal snags $17 mln Series C

By Iris Dorbian — 10 months ago

RedSeal, a cybersecurity analytics platform provider, has relaunched with $17 million in Series C funding. The investors included Tyco, MATH Venture Partners, Pallasite Ventures, DRW, Venrock, Sutter Hill, Icon Ventures, Leapfrog and Olympic Ventures.

Continue

Aeglea Biotherapeutics snags $44 mln Series B

By Iris Dorbian — 11 months ago

Aeglea Biotherapeutics Inc, a biopharmaceutical company focused on treating tumor metabolism, has raised $44 million in Series B funding. Return backers Lilly Ventures and Novartis Venture Fund led the round with participation from other investors that included UT Horizon Fund, OrbiMed, Jennison Associates (on behalf of clients), Venrock, RA Capital Management, Rock Springs Capital, Ally Bridge Group and Cowen Investments.

Continue